Your browser doesn't support javascript.
loading
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.
Smith, James M; Barlaam, Bernard; Beattie, David; Bradshaw, Lauren; Chan, Ho Man; Chiarparin, Elisabetta; Collingwood, Olga; Cooke, Sophie L; Cronin, Anna; Cumming, Iain; Dean, Emma; Debreczeni, Judit É; Del Barco Barrantes, Iván; Diene, Coura; Gianni, Davide; Guerot, Carine; Guo, Xiaoxiao; Guven, Sinem; Hayhow, Thomas G; Hong, Ted; Kemmitt, Paul D; Lamont, Gillian M; Lamont, Scott; Lynch, James T; McWilliams, Lisa; Moore, Shaun; Raubo, Piotr; Robb, Graeme R; Robinson, James; Scott, James S; Srinivasan, Bharath; Steward, Oliver; Stubbs, Christopher J; Syson, Karl; Tan, Lixiang; Turner, Oliver; Underwood, Elizabeth; Urosevic, Jelena; Vazquez-Chantada, Mercedes; Whittaker, Amy L; Wilson, David M; Winter-Holt, Jon J.
Afiliação
  • Smith JM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Barlaam B; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Beattie D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Bradshaw L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Chan HM; Research and Early Development, Oncology R&D, AstraZeneca, Waltham 02451, United States.
  • Chiarparin E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Collingwood O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Cooke SL; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Cronin A; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Cumming I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Dean E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Debreczeni JÉ; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Del Barco Barrantes I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Diene C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Gianni D; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Guerot C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Guo X; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Guven S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Hayhow TG; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Hong T; Research and Early Development, Oncology R&D, AstraZeneca, Waltham 02451, United States.
  • Kemmitt PD; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Lamont GM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Lamont S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Lynch JT; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • McWilliams L; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Moore S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Raubo P; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Robb GR; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Robinson J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Scott JS; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Srinivasan B; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Steward O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Stubbs CJ; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Syson K; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Tan L; Pharmaron Beijing Company, Ltd., Beijing 100176, P. R. China.
  • Turner O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Underwood E; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Vazquez-Chantada M; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Whittaker AL; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Wilson DM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
  • Winter-Holt JJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
J Med Chem ; 67(16): 13604-13638, 2024 Aug 22.
Article em En | MEDLINE | ID: mdl-39080842
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína-Arginina N-Metiltransferases / Inibidores Enzimáticos Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína-Arginina N-Metiltransferases / Inibidores Enzimáticos Idioma: En Ano de publicação: 2024 Tipo de documento: Article